| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Ezetimibe phenoxy glucuronide targets the same cholesterol absorption pathway as its parent drug. Ezetimibe is a selective inhibitor of cholesterol absorption in the gut. The glucuronide metabolite is less active than the parent drug but is a major circulating metabolite in humans.
|
|---|---|
| ln Vitro |
In vitro, Ezetimibe phenoxy glucuronide is characterized as a major metabolite of Ezetimibe. It is formed by glucuronidation of the phenoxy group. The compound is less active as a cholesterol absorption inhibitor compared to the parent drug but is an important metabolite for pharmacokinetic studies.
|
| ln Vivo |
Ezetimibe is absorbed in the small intestine following oral administration, and over 80% of the medication is converted into ezetimibe glucuronic acid through metabolism [1].
In vivo, Ezetimibe phenoxy glucuronide is a major circulating metabolite following Ezetimibe administration. It is formed in the liver and intestine and contributes to the overall pharmacokinetic profile of the parent drug. The compound is used as a reference standard for analytical method development and quality control. |
| Enzyme Assay |
In vitro assays for Ezetimibe phenoxy glucuronide typically involve analytical method development using HPLC or LC-MS. The compound is used as a reference standard to identify and quantify the metabolite in Ezetimibe samples. Its retention time and mass spectrum are characterized for method validation.
|
| Cell Assay |
For in vitro cell-based assays, Ezetimibe phenoxy glucuronide is not typically used, as it is a metabolite and not a pharmacological agent. It could be used to study its potential effects on cholesterol absorption if necessary, but its primary role is as an analytical reference standard.
|
| Animal Protocol |
In vivo animal studies with Ezetimibe phenoxy glucuronide are not typically performed, as it is a metabolite and not a therapeutic candidate. Its use is confined to analytical and pharmacokinetic studies. The compound is used as a reference standard for the quantification of Ezetimibe and its metabolites in biological samples.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Ezetimibe-glucuronide is a known human metabolite of ezetimibe. Ezetimibe phenoxy glucuronide (CAS: 190448-57-8) has a molecular weight of 584.53 g/mol and a molecular formula of C30H29F2NO9. Appearance: solid powder. Purity: ≥95%. Storage: -20°C. The compound is a major metabolite of Ezetimibe. |
| Toxicity/Toxicokinetics |
Ezetimibe phenoxy glucuronide is a research compound and is not approved for human therapeutic use. As a metabolite standard, it is used in very small quantities and does not pose significant toxicity risks under normal handling. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Ezetimibe phenoxy glucuronide is a major metabolite of Ezetimibe, a selective inhibitor of cholesterol absorption. It is formed by glucuronidation of the phenoxy group. It is not FDA-approved as a drug and is intended for research and analytical use only.
|
| Molecular Formula |
C30H29NO9F2
|
|---|---|
| Molecular Weight |
585.54936
|
| Exact Mass |
585.181
|
| CAS # |
190448-57-8
|
| Related CAS # |
Ezetimibe phenoxy glucuronide-d4;1426174-41-5;Ezetimibe phenoxy glucuronide-d4-1;2798007-90-4
|
| PubChem CID |
9894653
|
| Appearance |
White to pink solid powder
|
| Melting Point |
140-150ºC
|
| Index of Refraction |
1.65
|
| LogP |
2.518
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
42
|
| Complexity |
921
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O
|
| InChi Key |
UOFYCFMTERCNEW-ADEYADIWSA-N
|
| InChi Code |
InChI=1S/C30H29F2NO9/c31-17-5-1-15(2-6-17)22(34)14-13-21-23(33(28(21)38)19-9-7-18(32)8-10-19)16-3-11-20(12-4-16)41-30-26(37)24(35)25(36)27(42-30)29(39)40/h1-12,21-27,30,34-37H,13-14H2,(H,39,40)/t21-,22+,23-,24+,25+,26-,27+,30-/m1/s1
|
| Chemical Name |
(2S,3S,4S,5R,6S)-6-[4-[(2S,3R)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-2-yl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~170.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7078 mL | 8.5390 mL | 17.0780 mL | |
| 5 mM | 0.3416 mL | 1.7078 mL | 3.4156 mL | |
| 10 mM | 0.1708 mL | 0.8539 mL | 1.7078 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA